Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 16/20 | 0.52 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.52 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.52 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.52 |
| ▸ | PRKDC | P78527 | 1/20 | 0.52 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL189397 | 0.89 | PIK3CG (0.55) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL189875 | 0.89 | PIK3CG (0.53) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL188533 | 0.82 | PIK3CG (0.55) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL188873 | 0.81 | PIK3CG (0.57) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL188756 | 0.81 | PIK3CG (0.57) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL14053338 | 0.81 | PIK3CG (0.66) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL189112 | 0.80 | PIK3CG (0.61) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL188736 | 0.80 | PIK3CD (0.58) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL189516 | 0.80 | PIK3CG (0.63) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL189170 | 0.80 | PIK3CG (0.63) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2056829-B9 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | EXELIXIS INC (US) | 2012-09-26 | — | — | EP | disclosed |
| EP-2056829-B1 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | EXELIXIS INC (US) | 2012-01-04 | — | — | EP | disclosed |